BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol 2022;13:927153. [PMID: 35757715 DOI: 10.3389/fimmu.2022.927153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Xu Y, Dang X, Zhu Z, Qian W, Liang A, Han W. Challenges and optimal strategies of CAR T therapy for hematological malignancies. Chin Med J (Engl) 2023. [PMID: 36848181 DOI: 10.1097/CM9.0000000000002476] [Reference Citation Analysis]
2 Jolles S, Giralt S, Kerre T, Lazarus HM, Mustafa SS, Ria R, Vinh DC. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review. Front Oncol 2023;13:1098326. [PMID: 36824125 DOI: 10.3389/fonc.2023.1098326] [Reference Citation Analysis]
3 Al-Ibraheem A, Abdlkadir AS, Juweid ME, Al-Rabi K, Ma'koseh M, Abdel-Razeq H, Mansour A. FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects. Cancers (Basel) 2023;15. [PMID: 36831405 DOI: 10.3390/cancers15041063] [Reference Citation Analysis]
4 McGann M, Gaffney KJ, Davis JA, Smith D, Hashmi H. Organ toxicities associated with chimeric antigen receptor T-cell therapy. Leuk Lymphoma 2023;64:491-4. [PMID: 36416619 DOI: 10.1080/10428194.2022.2148213] [Reference Citation Analysis]
5 Ansah EO, Baah A, Agyenim EB. Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies. Advances in Cell and Gene Therapy 2023;2023:1-9. [DOI: 10.1155/2023/8030440] [Reference Citation Analysis]
6 Zhang X, Wu J, Qiao L, Chen L, Chen C, Zhang H, Luo R, Xiao Y. Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell malignancies with bulky disease. Front Oncol 2023;13:1008828. [PMID: 36776338 DOI: 10.3389/fonc.2023.1008828] [Reference Citation Analysis]
7 Jain S, Sheth RA. Modulating the tumor immune microenvironment with locoregional image-guided interventions. Front Immunol 2022;13:1057597. [PMID: 36685505 DOI: 10.3389/fimmu.2022.1057597] [Reference Citation Analysis]
8 Wang Z, Chen C, Wang L, Jia Y, Qin Y. Chimeric antigen receptor T-cell therapy for multiple myeloma. Front Immunol 2022;13:1050522. [PMID: 36618390 DOI: 10.3389/fimmu.2022.1050522] [Reference Citation Analysis]
9 Wu H, Chen C, Gu L, Li J, Yue Y, Lyu M, Cui Y, Zhang X, Liu Y, Zhu H, Liao X, Zhang T, Sun F, Hu W. B cell deficiency promotes the initiation and progression of lung cancer. Front Oncol 2022;12:1006477. [DOI: 10.3389/fonc.2022.1006477] [Reference Citation Analysis]